Posting content from the Journal of Cystic Fibrosis, European Cystic Fibrosis Society and Cystic Fibrosis Research News. Follows do not indicate endorsement.
We are seeking an early career researcher to run this Twitter feed, promoting #JournalCF content and European #cysticfibrosis Society events/news. This is a voluntary role. To apply, please DM a CV and a letter of interest/qualifications by 31st January.
Seeking applications for an Administrative & Communication Assistant. It is a full time position, split equally between #cysticfibrosis Europe and the ECFS patient registry. Deadline for applications is 1st February 2020. For more information, visit https://t.co/tWKmnlyEtk
#JournalCF Letter to the Editor explores the utility of n-of-1 trials to expand access to CFTR modulators for rare #cysticfibrosis mutations.
https://t.co/s2v30TcUMp
To foster basic and translational research on #cysticfibrosis, a number of European Post-Doctoral 2-year duration Research Fellowships will be supported the ECFS and CF Europe.
More information on: https://t.co/NtQzZJOKjk
#openaccess publication in #JournalCF on how rescue of #cysticfibrosis W1282X-CFTR requires inhibition of nonsense mediated decay alongside corrector and potentiator therapy. https://t.co/OnkqS9jock
The abstract submission deadline for the ECFS #cysticfibrosis Basic Science Conference is this Friday 10 January 23:59 (CET)!! Submit your abstract here https://t.co/1djJvwJ8Ca
Data from a recent #JournalCF manuscript finds strong toll-like receptor responses in #cysticfibrosis patients are associated with higher lung function.
https://t.co/iZF58nXBta
Also #openaccess in #JournalCF, alterations of bone microarchitecture and composition at birth in #cysticfibrosis pigs suggest bone defects may be a primary aspect of disease.
https://t.co/b8SPCnUIPf
An #openaccess#JournalCF publication on use of ivacaftor in #cysticfibrosis with residual function: Lung function results from an N-of-1 study. https://t.co/lPDNx59ljc
Published in #JournalCF is new evidence demonstrating the utility of lung clearance index as an effective primary endpoint in #cysticfibrosis phase III clinical trial. https://t.co/cTz6WNsCuw
#JournalCF Letter to the Editor - positive clinical outcomes following ivacaftor treatment of #cysticfibrosis genotype 3272β26A > G/Q493X. https://t.co/AHljFeQBjC
Read results from a survey of #cysticfibrosis community and clinicians about treatment withdrawal research to reduce treatment burden. #JournalCF https://t.co/VcSD2JtvMP
New evidence is emerging that has to be considered as an additional opportunistic pathogen in #cysticfibrosis. Read further in #JournalCF. https://t.co/L3lT3cWKEb
Read a review of the new insights gained into how small molecules for #cysticfibrosis can rescue CFTR structure and function. #JournalCF https://t.co/glHUfzAJbn
New #JournalCF study asks - Can exercise replace airway clearance techniques in #cysticfibrosis? A survey of patients and healthcare professionals. https://t.co/EY5m6A6MNS
#JournalCF study used a questionnaire to summarise the lived experience of #cysticfibrosis treatment burden and suggest research themes aimed at reducing burden. https://t.co/hkrzdwbME2
Intestinal organoids function varied between #cysticfibrosis subjects with homozygous F508del, correlates with pulmonary and nutritional parameters and may underly clinical heterogeneity. #JournalCF https://t.co/xVbJozw1g2
#CFResearchNews: Could quality improvement programs improve adherence to #cysticfibrosis related diabetes screening and management guidelines? https://t.co/RuNy8ccCce